date:Feb 09, 2022
ntion study.
Another aspect was the absence of a dose-response analysis. However, Nestl provided a post-hoc dose-response analysis of the results, showing a statistically significant linear relationship between the dose of beta-glucans and the placebo-adjusted percent reduction in the post-prandial glucose response.
Possibilities for a new application
EFSA notes that although the dose-response analysis was missing from Nestls initial application, it could be submitted in the context of a new a